Arvinas【ARVN】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

25.16

買値

23.87

売値

25.92

出来高

663,587

24.81 日の範囲 25.75

17.12 52 週間の範囲 53.08

時価総額

1.729B

前日終値

25.34

始値

25.275

時刻

24.97

最終取引時間

財務取引量

US$ 16,799,933

VWAP

25.3169

平均取引量 (3 か月)

523,065

発行済株式数

68,713,098

配当利回り

PER

-4.67

1 株当たり利益 (EPS)

-5.35

歳入

78.5M

純利益

-367.3M

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.arvinas.com

本社

Wilmington, Delaware, USA

設立

Arvinas Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker ARVN. The last closing price for Arvinas was US$25.34. Over the last year, Arvinas shares have traded in a share price range of US$ 17.12 to US$ 53.08.

Arvinas currently has 68,713,098 shares in issue. The market capitalisation of Arvinas is US$1.74 billion. Arvinas has a price to earnings ratio (PE ratio) of -4.67.

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-2.9393	-10.4604029282	28.0993	28.755	24.92	704861	26.87938582	CS
4	-2.5	-9.03832248735	27.66	29.6106	24.92	614409	26.90206543	CS
12	0.02	0.079554494829	25.14	29.6106	23.64	523065	25.96746602	CS
26	-6.98	-21.7174859988	32.14	37.38	23.095	711641	27.27837285	CS
52	7.73	44.3488238669	17.43	53.08	17.12	753213	32.72530565	CS
156	-59.69	-70.347672363	84.85	85.57	13.57	557932	38.05925929	CS
260	-3.59	-12.4869565217	28.75	108.465	13.57	543296	45.32179851	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MTEMMolecular Templates Inc	US$ 0.60 (86.28%)	331.49M
QUBTQuantum Computing Inc	US$ 4.43 (66.54%)	232.55M
OMEROmeros Corporation	US$ 6.96 (66.11%)	14.23M
ADGMAdagio Medical Holdings Inc	US$ 3.71 (57.87%)	2.66M
VVPRVivoPower International PLC	US$ 1.18 (50.47%)	5.92M
SOWGSow Good Inc	US$ 4.23 (-56.88%)	2.88M
WCTWellchange Holdings Company Limited	US$ 4.08 (-48.35%)	1.27M
NVCTNuvectis Pharma Inc	US$ 5.73 (-46.30%)	1.63M
KXINKaixin Holdings	US$ 2.525 (-39.59%)	4.47M
TRNRInteractive Strength Inc	US$ 3.59 (-38.42%)	1.23M
ELABElevai Labs Inc	US$ 0.024658 (-0.17%)	1.79B
XTIAXTI Aerospace Inc	US$ 0.0565 (-1.22%)	363.98M
MTEMMolecular Templates Inc	US$ 0.60 (86.28%)	331.48M
SVMHSRIVARU Holding Ltd	US$ 0.0268 (10.74%)	245.93M
QUBTQuantum Computing Inc	US$ 4.43 (66.54%)	228.27M